louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00066209: Investigating Severe Acute Respiratory Syndrome (SARS)
Official title: An Investigation of the Inflammatory Response in Severe Acute Respiratory Syndrome (SARS)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: SARS Virus
Keywords: Inflammation
Coronavirus
Immunity
Interferon
Cytokine
Severe Acute Respiratory Syndrome
SARS
Healthy Volunteer
HV
Lead sponsor: National Institutes of Health Clinical Center (CC)
Sponsor class: NIH
First posted: 2003-08-06
Enrollment: 400
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes

Brief summary: Severe Acute Respiratory Syndrome (SARS) is a newly recognized illness that can be fatal.

The purpose of this study is to better understand SARS by collecting samples of blood and other body fluids of people who have been exposed to SARS or who are suspected to have the illness.

Up to 300 volunteers aged 18 years or older will be enrolled in this study. Participants will donate blood samples and, if appropriate, samples of fluid from the lungs, nose, or throat. Researchers will test these samples for proteins that control or mediate inflammatory or immune responses. The patterns of these proteins will reveal how SARS affects the body and the efforts the body makes to fight off the infection.

Detailed description: Severe acute respiratory syndrome (SARS) is a newly recognized illness associated with substantial mobidity and mortality. Patients develop fever followed by rapidly progressive and even fatal respiratory disease. SARS is associated with infection with a novel coronavirus. The evaluation of the inflammatory responses evoked by SARS may yield information regarding its pathogenesis and help with patient management. This protocol, then, merely aims to study disease pathogenesis and natural history, by studying samples and data that are collected by outside physicians or physicians at the Clinical Center and sent for evaluation of the inflammatory response.

Eligibility criteria: * INCLUSION CRITERIA - CASES:

Patients fulfilling the CDC case definition or WHO definition for suspected or probable SARS.

Newly identified patients found to have recovered from SARS can also be enrolled.

EXCLUSION CRITERIA - CASES:

Patients diagnosed with alternative illnesses as the cause of the symptoms.

INCLUSION CRITERIA - HEALTHY VOLUNTEERS:

For the purpose of this study, a healthy volunteer is defined as a healthy male or female, age 18 and above.

Volunteers will be excluded if they have a pre-existing or concurrent serious chronic medical or psychiatric illness.

Chronic medication use will be evaluated on a case-by-case basis.

They will also be excluded if they have received an investigational drug in the past 3 months.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Bethesda
country: United States
facility: National Institutes of Health Clinical Center, 9000 Rockville Pike
state: Maryland
Study officials:
References:
Clinical trial NCT03695809: The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer
Official title: Far Eastern Memorial Hospital
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Vulvar Cancer, G9a Protein
Lead sponsor: Far Eastern Memorial Hospital
Sponsor class: OTHER
Collaborators: name: Gynecologic Oncology Group
First posted: 2018-10-04
Enrollment: 30
Sex: FEMALE
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients' clinical characteristerics including age, stage, pathologic finding, and follow-up data were recorded from charts.

Brief summary: To assess the G9a expression in vulvar cancer

Detailed description: Vulvar cancer can be treated with surgery, radiotherapy or chemoradiotherapy. Recurrence of vulvar cancer generally can be detected by imaging study. Currently, there is a paucity of sensitive marker to detect the recurrence of vulvar cancer. G9a is a recently identified protein with histone lysine methyltransferase activity. The role of histone methyltransferases in promoting tumorigenesis and progression of human cancers has been noted in some cancers, such as ovarian cancer, endometrial cancer and cervical cancer. The role of G9a protein in vulvar cancer remains obscure.

All female patients with vulvar cancer or vulvar intraepithelial neoplasm II /III who underwent surgery at Far Eastern Memorial Hospital from January 2003 will be included. All patients' clinical characteristerics including age, stage, pathologic finding, and follow-up data will be recorded from chart review.

The archived specimens will be used for immunohistochemical staining of G9a protein. Tumor size, local invasion, lymph node metastasis, and final disease stage will be determined. Correlation will be performed between G9a and clinical outcome of vulvar cancer.

Eligibility criteria: Inclusion Criteria:

* All female patients with vulvar cancer or vulvar intraepithelial neoplasm II /III who underwent surgery at Far Eastern Memorial Hospital from January 2003 were included.

Exclusion Criteria:

* N/A

Primary outcomes:
measure: Correlation between clinical outcome of vulvar cancer and G9a
timeFrame: 5 years
Secondary outcomes:
measure: Correlation between histopathologic features of vulvar cancer and G9a
timeFrame: 1 year
Other outcomes:
measure: Correlation between histopathologic features of vulvar intraepithelial neoplasm and G9a
timeFrame: 1 year
Locations:
city: Banqiao
country: Taiwan
facility: Far Eastern Memorial Hospital
state: New Taipei
Study officials:
References:
Clinical trial NCT02995109: Sun Protection Factor Assay (338/2016)
Official title: Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sunscreening Agents
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2016-12-16
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: To evaluate the Sun Protection Factor efficacy on human skin.


Eligibility criteria: Inclusion Criteria:

* Fitzpatrick Skin Type l, ll and/or lll for UVB testing. Fitzpatrick Skin Type ll, lll and/or lV for UVA testing.
* Male and female.
* Aged between 18-70 years old.
* Good health as determined from the HRL SHF (Subject History Form).
* Signed and dated Informed Consent Form.
* Signed and dated HIPAA (Health Insurance Portability and Accountability Act) form.
* An unambiguous MED (Minimal Erythema Dose) or MPPD (Minimal Persistent Pigment Darkening Dose)

Exclusion Criteria:

* Subjects on test at any other research laboratory or clinic.
* Known allergy or sensitivity to sunscreens, cosmetics and toiletries, topical drugs and/or ultraviolet light.
* Pre-existing dermatologic conditions which have been diagnoses by a medical professional (e.g. psoriasis, eczema, etc.)which would interfere with this study.
* Pre-existing other medical conditions (e.g. adult asthma, diabetes).
* Treatment with antihistamines or corticosteroids within one week prior to initiation of the test.
* Treatment with antibiotics within two weeks prior to initiation of the test.
* Chronic medication which could affect the results of the study.
* Known pregnant or nursing women.

Primary outcomes:
measure: Minimal Erythema Dose (MED)
timeFrame: Up to 15 minutes
measure: Minimal Persistent Pigment Darkening Dose (MPPD)
timeFrame: Up to 15 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Union
country: United States
state: New Jersey
Study officials:
References:
Clinical trial NCT01751009: Effects of Fortified Complementary Foods on Vitamin A Status and Body Pool Size in Ghanaian Infants.
Official title: A Randomised Controlled Home-based Trial of the Effects of Fortified Complementary Foods on Vitamin A Status and Body Pool Size in Ghanaian Infants.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Malnutrition
Keywords: vitamin A, complementary foods, malnutrition, children
Lead sponsor: Kintampo Health Research Centre, Ghana
Sponsor class: OTHER
Collaborators: name: University of Wisconsin, Madison
First posted: 2012-12-17
Enrollment: 93
Sex: ALL
Minimum age (years): 6
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study tried to prove that children given food supplements containing vitamin A would have better liver vitamin A stores than children given food supplements without vitamin A over a 5 month period.

Detailed description: The study wanted to assess the effect of fortification of home based complementary foods on vitamin A status in Ghanaian children who receive food supplements known as Sprinkles. The study assessed the vitamin A status and body pool size in children using a test known as the modified relative dose response test (MRDR) tests and stable 13C2 retinol as a tracer, among those who receive Sprinkles with or without vitamin A through home fortification of complementary foods.

Eligibility criteria: Inclusion Criteria:

Informed consent of mother of eligible children aged 6-12 months.

Willingness to remain in the study area for entire duration of the study.

Willingness to agree to feed the child with supplied micronutrient supplements for duration of study.

The child should have started taking complementary foods in addition to breast milk.

Child's haemoglobin level of at least 70 g/L.

Exclusion Criteria:

Child's haemoglobin level less than 70 g/L.

Unable to give informed consent

Primary outcomes:
measure: Vitamin A status after 5 months supplementation
timeFrame: 5 months
Secondary outcomes:
measure: acceptability of home based fortified vitamin A supplements
timeFrame: 5 months
Other outcomes:
Locations:
city: Kintampo
country: Ghana
facility: Kintampo North Municipality
Study officials:
affiliation: University of Wisconsin, Madison
name: Sherry Tanumihardjo, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01116609: Local Effects of Epinephrine on Lactate, Glucose, Lipid and Protein Metabolism in Bilaterally Perfused Human Legs
Official title: Local Effects of Epinephrine on Lactate, Glucose, Lipid and Protein Metabolism in Bilaterally Perfused Human Legs
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: Phenylalanine
Palmitate
hyperinsulinemic-euglycemic-clamp
Effects of epinephrine in healthy volunteers
Lead sponsor: University of Aarhus
Sponsor class: OTHER
First posted: 2010-05-05
Enrollment: 10
Sex: MALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to define the local metabolic effects of epinephrine in the bilaterally perfused human leg.


Eligibility criteria: Inclusion Criteria:

* Male

Exclusion Criteria:

* Comorbidity
* Females

Primary outcomes:
measure: Arterio-Venous balances of metabolites
timeFrame: 6 hours infusion
Secondary outcomes:
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Medical research laboratories, Aarhus University Hospital
Study officials:
affiliation: Medical Research Laboratories, Aarhus University, Denmark
name: Niels Moller, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02875509: Wound Inflammatory Cells After Cardiac Surgery
Official title: Wound Infammatory Cells After Cardiac Surgery and the Patients´Survival. A Sixteen Years Follow-up Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sternotomy Wound
Lead sponsor: Turku University Hospital
Sponsor class: OTHER_GOV
First posted: 2016-08-23
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergone open heart surgery

Brief summary: One hundred patients, aged from 41 to 78 years, underwent open heart surgery in the years 1998-1999 and were studied by using the Cellstick device for harvesting wound inflammatory cells during the first 24 hours after surgery. The results of the differential count were computerized by using artificial neural network for obtaining wound inflammatory cell node (WICN). The patients were followed up for sixteen years or to the death. WICN values were compared with the patients´ survival.


Eligibility criteria: Inclusion Criteria:

* Elective operations

Exclusion Criteria:

* Urgency operations

Primary outcomes:
measure: death
timeFrame: 16 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Turku University Hospital
name: Timo JA Savunen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06616909: Advance Care Planning Impact on the Consistency of Older Adults With Lung Cancer and Their Potential Surrogates Regarding Life-Sustaining Treatment Preferences
Official title: Advance Care Planning Impact on the Consistency of Older Adults With Lung Cancer and Their Potential Surrogates Regarding Life-Sustaining Treatment Preferences
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Advanced Care Planning (ACP)
ELDERLY PEOPLE
Lung Cancer (NSCLC)
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2024-09-27
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Background: Globally and nationally, malignant tumors persist as the leading cause of high incidence and mortality rates. In Taiwan, cancer tops the list of causes of death, with the elderly being predominantly affected, especially by lung cancer, which is the most prevalent type with the highest mortality and incidence rates in the nation. The Patient Autonomy Rights Act, implemented by the government in 2019, is designed to promote advance medical care consultation in medical institutions, respecting patient's autonomous decisions. In Chinese culture, medical decisions are typically family-oriented rather than individualistic, leading the elderly to frequently rely on their relatives'choices. This cultural practice may prevent meaningful conversations between potential agents and the elderly, causing misunderstandings of the elderly's preferences and affecting the consistency of medical decisions. Presently, interventions like board games for Advance Care Planning (ACP) are not well received, highlighting the need for more captivating content in intervention strategies.


Eligibility criteria: Inclusion Criteria:

1. lung cancer age ≧ 60
2. The elderly with lung cancer are conscious and have no severe visual or hearing impairment.

3.3. The potential agent is designated by the elderly person with lung cancer who may be a family member who may make medical decisions in the future. The potential agent must be at least 18 years old.

Exclusion Criteria:

1. People with severe hearing loss and visual impairment who are unable to communicate in Mandarin and Taiwanese.
2. The potential agent is under 18 years old

Primary outcomes:
measure: Consistency in subsistence disposal preferences between the elderly and potential agents
timeFrame: Outcome Measure Total (3 Time Points): First time: before intervention .Second time: 2 weeks after intervention . Last time: 6 weeks after intervention
Secondary outcomes:
measure: STAI
timeFrame: Outcome Measure Total (4 Time Points): First time: Before intervention. Second time: After intervention. Third time: 2 weeks after intervention .Last time: 6 weeks after intervention
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
References:
Clinical trial NCT06271109: Short Term Surgical Outcomes of Anatomical Versus Non Anatomical Laparoscopic Liver Resection for Liver Tumors
Official title: Short Term Surgical Outcomes of Anatomical Versus Non Anatomical Laparoscopic Liver Resection for Liver Tumors
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Liver Neoplasms
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2024-02-21
Enrollment: 50
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: patient with liver neoplasms candidate for resection and fit for surgery

Brief summary: aimed to discuss the short term surgical outcomes of Anatomical versus Non anatomical laparoscopic Liver resection for Liver tumors.

Detailed description: This study aimed to be both prospective and retrospective study including the cases of laparoscopic liver resection that was done and will be done during the period from December 2021 to June 2025. This study will include cohort of patients who met the eligible criteria.

Complete history taking with special concern to the following:

* Age, sex and life style.
* present medical history: hepatic condition and other debilitating diseases.
* Past medical History: blood transfusion, hepatitis, liver cirrhosis and history of hospital admission.

Complete local examination of the abdomen including:

* Local examination of the skin overlying for any signs of infection, radiation fibrosis and or presence of sinuses
* Percussion for presence of ascites
* Palpation for cirrhosis or any palpable masses investigations will be carried

  1. Ultrasonography: routine abdominal US for every case.
  2. Triphasic CT scan
  3. CT volumetric study to evaluate remaining liver volume when needed.
  4. Dynamic or triphasic MRI if needed
  5. Metastatic work up (CT chest, bone scan and PET scan in selected patients).
  6. Preoperative histopathological examination when needed.
  7. routine laboratory investigations

Eligibility criteria: Inclusion Criteria:

* all patients diagnosed with liver tumors (benign and malignant) lesions suitable for laparoscopic liver resection (Anatomical and Non anatomical)
* Patients with Child Pugh A and early B
* Patients Fit for surgery as regard anesthesia
* Patients who accept to participate in the study and sign an informed consent

Exclusion Criteria:

* Patients with Child Pugh late B\&C liver disease.
* For Patients with hepatocellular carcinoma BCLC stage C\&D (extra hepatic spread and macro vascular invasion)
* Patients with contraindications to laparoscopic surgery and (or) unfit for surgery.

Primary outcomes:
measure: complete resection of the neoplasm
timeFrame: 3.5 years
Secondary outcomes:
measure: residual liver tissue
timeFrame: 3.5 years
measure: recurrence rate
timeFrame: 3.5 years
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag University
Study officials:
References:
Clinical trial NCT04209309: Repetitive Transcranial Magnetic Stimulation as a Potential Tool to Reduce Sexual Arousal
Official title: Repetitive Transcranial Magnetic Stimulation as a Potential Tool to Reduce Sexual Arousal
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Transcranial Magnetic Stimulation
Keywords: sexual arousal
Lead sponsor: University of Regensburg
Sponsor class: OTHER
First posted: 2019-12-24
Enrollment: 19
Sex: MALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Hyper- and hyposexuality occur frequently in a variety of psychiatric disorders and are difficult to treat. While there is meta-analytic evidence for the significant effect of non-invasive brain stimulation on drug and food craving, no study has investigated the potential of this technique to modulate sexual behavior. The efficacy of a single session of high-frequency repetitive transcranial magnetic stimulation (rTMS) over the left or right dorsolateral prefrontal cortex (DLPFC) to reduce sexual arousal was tested against a sham stimulation.

To test this hypothesis, we employed a randomized, double-blind, sham-controlled crossover study design. Nineteen healthy male participants received high-frequency rTMS over the left DLPFC, high-frequency rTMS over the right DLPFC and sham rTMS (each 10 Hz; 110% resting motor threshold; 60 trains with 50 pulses) in randomized and counterbalanced order with a one-week interval between stimulation sessions to avoid carryover effects. Participants were exposed to neutral and sexual cues before and after each intervention and rated their sexual arousal after each block of cue presentation.


Eligibility criteria: Inclusion Criteria:

* motor threshold below 55%
* informed consent
* male
* 18-50 years
* heterosexual
* right handedness

Exclusion Criteria:

* contraindication for TMS
* somatic or mental illnesses
* intake of psychoactive drugs
* left handedness
* homo- or bisexual
* paraphilia

Primary outcomes:
measure: Change of sexual arousal
timeFrame: immediately before and after the single session of rTMS
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: